Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
Research Letter

Genomic Evidence of In-Flight SARS-CoV-2 Transmission, India to Australia, April 2021

Freya Hogarth, Pasqualina Coffey, Laura Goddard, Sarah Lewis, Shereen Labib, Mathilda Wilmot, Patiyan Andersson, Norelle Sherry, Torsten Seemann, Benjamin P. Howden, Kevin Freeman, Robert Baird, Ian Hosegood, Kathleen McDermott, Nick Walsh, Ben Polkinghorne, Catherine Marshall, Jane Davies, Vicki Krause, and Ella M. MeumannComments to Author 
Author affiliations: Australian Government Department of Health, Canberra, Australian Capital Territory, Australia (F. Hogarth); The Australian National University, Canberra (F. Hogarth, B. Polkinghorne); Centre for Disease Control, Darwin, Northern Territory, Australia (P. Coffey, L. Goddard, S. Lewis, S. Labib, V. Krause); The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (M. Wilmot, P. Andersson, N. Sherry, T. Seemann, B.P. Howden); Royal Darwin Hospital, Darwin (K. Freeman, R. Baird, C. Marshall, J. Davies, E.M. Meumann); Qantas Airways Limited, Mascot, New South Wales, Australia (I. Hosegood); National Critical Care and Trauma Response Centre, Darwin (K. McDermott, N. Walsh); Menzies School of Health Research and Charles Darwin University, Darwin (J. Davies, E.M. Meumann)

Main Article

Table

Detailed information of case-patients belonging to SARS-CoV-2 genomic clusters detected after 2 flights from India to Darwin, Northern Territory, Australia, on April 15 and April 17, 2021*

Cluster and case-patient Age group, y/sex Family group Virus Pango lineage Cycle threshold Symptom onset date Date tested positive Vaccinated Seat no.
1
A 30–39/M None B.1.617.2 14.3 Asymptomatic Apr 15 N 56B
B 40–49/M I B.1.617.2 15.6 Asymptomatic Apr 15 N 43D
C 20–29/F I B.1.617.2 11.6 Apr 20 Apr 20 N 43E
D 1–5/F I B.1.617.2 11.6 Asymptomatic Apr 20 N 43F
E <1/M I B.1.617.2 12.2 Asymptomatic Apr 20 N 43D
F 30–39/M II B.1.617.2 22.6 Apr 20 Apr 20 N 43K
G 10–19/F II B.1.617.2 18 Apr 20 Apr 20 N 43H
H 1–5/M II B.1.617.2 26.5 Asymptomatic Apr 20 N 43J
I
 <1/F
 II
 B.1.617.2
 19
 Asymptomatic
 Apr 20
 N
 43K
2
J 20–29/F None B.1.617.1 12.4 Apr 16 Apr 15 N 42A
K 50–59/M None B.1.617.1 16.6 Apr 17 Apr 20 N 51H
L 1–5/M III B.1.617.1 22 Asymptomatic Apr 22 N 42B
M 1–5/M III B.1.617.1 18.1 Apr 22 Apr 22 N 43B
N
 30–39/F
 III
 B.1.617.1
 20
 Asymptomatic
 Apr 22
 N
 43B
3
O 50–59/F IV B.1.617.2 14.9 Asymptomatic Apr 15 Y 3E
P 60–69/M IV B.1.617.2 14.9 Apr 15 Apr 16 Y 3F
Q
 10–19/F
 None
 B.1.617.2
 11.4
 Asymptomatic
 Apr 17
 N
 4E
4
R 50–59/M V B.1.617.2 14.9 Asymptomatic Apr 22 N 55A
S
 60–69/F
 V
 B.1.617.2
 14.9
 Apr 22
 Apr 23
 N
 55B
5
T 10–19/M B.1.617.2 11.7 Apr 17 Apr 18 N 48C
U 30–39/M VI B.1.617.2 16.1 Asymptomatic Apr 24 N 48B
V 30–39/F VI B.1.617.2 12.8 Not available Apr 24 N 48A
W
 1–5/M
B.1.617.2
 24.5
 Asymptomatic
 Apr 24
 N
 48J
6
X 30–39/M VII B.1.1.7 10.9 Asymptomatic Apr 17 N 43F
Y 40–49/M VII B.1.1.7 13.1 Asymptomatic Apr 17 N 43E

Main Article

Page created: April 28, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external